Bristol's Opdivo Delivers, But CheckMate 227 Uncertainties Cloud Quarter

27 Oct 2017

• By Emily Hayes

The use of the emerging tumor mutation burden biomarker and its relevance to the outcome of the CheckMate 227 study of Opdivo/Yervoy in first-line lung cancer was a hot topic during Bristol's Q3 earnings call, but questions remain.

Bristol-Myers Squibb Co.'s PD-1 inhibitor Opdivo continues to deliver impressive sales despite increased competition, but uncertainties about the all-important CheckMate 227 study of combination use with Yervoy in first-line non-small cell lung cancer, including the relevance of tumor mutation burden as an emerging immuno-oncology biomarker, cast a bit of a cloud on the third quarter.

Bristol reported sales of about $1.3bn for Opdivo (nivolumab) for the third quarter, up 38% from the same period in 2016

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Stock Watch: Market Optimism Outshines Q1 Currency And Tariff Woes

07 May 2025

• By Andy Smith

The weak US dollar helped some companies reporting first-quarter results and hindered others reporting in stronger currencies. But even the impacts of currencies and Medicare modernization on first-quarter revenues were overlooked when an end to the trade wars seemed possible.

Vertex Sinks On Below-Consensus Revenue, Limited Sales From New Launches

06 May 2025

• By Mandy Jackson

Vertex is in need of diversification, but in addition to its lower-than-expected Q1 revenue, sales of the company’s newest CF drug Alyftrek and pain medicine Journavx disappointed.

BioNTech Aims To Diversify BNT323 Manufacturing As Filing Nears

05 May 2025

• By Alaric DeArment

The company plans to expand manufacturing of the HER2-targeting ADC beyond China and plans to file for US FDA approval in 2025.

Lilly’s Ricks Urges Trump To Pick Tax Incentives Over Tariffs

02 May 2025

• By Alaric DeArment

On Lilly’s Q1 earnings call, CEO David Ricks voiced concerns about the Trump Administration’s tariff policy, which he said could adversely affect Lilly and the industry as a whole.

Lilly And Alchemab Tap Into Resilient Individuals To Develop ALS Drug

06 May 2025

• By Andrew McConaghie

The pharma company is helping to validate the biotech’s model by developing a novel amyotrophic lateral sclerosis candidate, based on its novel approach that ‘turns drug discovery on its head’.